Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | cytochrome P450, family 2, subfamily C, polypeptide 9 | Starlite/ChEMBL | No references |
Homo sapiens | polymerase (DNA directed), eta | Starlite/ChEMBL | No references |
Homo sapiens | cytochrome P450, family 2, subfamily C, polypeptide 19 | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | cytochrome P450, family 3, subfamily A, polypeptide 4 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | cytochrome P450 | cytochrome P450, family 3, subfamily A, polypeptide 4 | 502 aa | 492 aa | 24.2 % |
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Leishmania major | cytochrome p450-like protein | cytochrome P450, family 2, subfamily C, polypeptide 19 | 490 aa | 411 aa | 23.1 % |
Mycobacterium tuberculosis | Probable cytochrome P450 136 Cyp136 | cytochrome P450, family 2, subfamily C, polypeptide 9 | 490 aa | 441 aa | 21.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.5371 | 0.6312 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0023 | 0.1035 | 0.5 |
Echinococcus granulosus | terminal deoxycytidyl transferase rev1 | 0.0023 | 0.1035 | 0.1216 |
Schistosoma mansoni | terminal deoxycytidyl transferase | 0.0023 | 0.1035 | 0.1216 |
Echinococcus granulosus | dna polymerase kappa | 0.0023 | 0.1035 | 0.1216 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0023 | 0.1058 | 0.1058 |
Brugia malayi | Cytochrome P450 family protein | 0.0023 | 0.1058 | 0.1058 |
Toxoplasma gondii | ImpB/MucB/SamB family protein | 0.0038 | 0.4604 | 0.5 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0038 | 0.4604 | 0.4775 |
Loa Loa (eye worm) | CYP4Cod1 | 0.0023 | 0.1058 | 0.1058 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0023 | 0.1035 | 0.5 |
Echinococcus multilocularis | terminal deoxycytidyl transferase rev1 | 0.0023 | 0.1035 | 0.1216 |
Leishmania major | DNA polymerase eta, putative | 0.0038 | 0.4604 | 0.4775 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0023 | 0.1058 | 0.1058 |
Giardia lamblia | DINP protein human, muc B family | 0.0023 | 0.1035 | 0.5 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0054 | 0.851 | 1 |
Mycobacterium ulcerans | cytochrome P450 185A4 Cyp185A4 | 0.0023 | 0.1058 | 1 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0023 | 0.1035 | 0.1035 |
Leishmania major | cytochrome p450-like protein | 0.0023 | 0.1058 | 0.0031 |
Trypanosoma cruzi | cytochrome P450, putative | 0.0023 | 0.1058 | 0.0031 |
Echinococcus granulosus | dna polymerase eta | 0.0054 | 0.851 | 1 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0054 | 0.851 | 0.851 |
Schistosoma mansoni | DNA polymerase eta | 0.0054 | 0.851 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0054 | 0.851 | 0.851 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0059 | 0.9685 | 0.9685 |
Brugia malayi | Cytochrome P450 family protein | 0.0023 | 0.1058 | 0.1058 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 1 | 1 |
Brugia malayi | Cytochrome P450 family protein | 0.0059 | 0.9685 | 0.9685 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0023 | 0.1035 | 0.5 |
Loa Loa (eye worm) | ImpB/MucB/SamB family protein | 0.0023 | 0.1035 | 0.1035 |
Schistosoma mansoni | rab geranylgeranyl transferase alpha subunit | 0.0023 | 0.1035 | 0.1216 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0023 | 0.1035 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 1 | 1 |
Echinococcus multilocularis | dna polymerase eta | 0.0054 | 0.851 | 1 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0023 | 0.1035 | 0.5 |
Trypanosoma brucei | cytochrome P450, putative | 0.0023 | 0.1058 | 0.0031 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0054 | 0.851 | 1 |
Trypanosoma cruzi | cytochrome P450, putative | 0.0023 | 0.1058 | 0.0031 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.5371 | 0.5371 |
Echinococcus multilocularis | dna polymerase kappa | 0.0023 | 0.1035 | 0.1216 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.5371 | 0.5371 |
Leishmania major | DNA polymerase eta, putative | 0.0054 | 0.851 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp1a2 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2d6 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | = 2.511886432 uM | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp3a4 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference |
AC50 (functional) | = 14.12537545 uM | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference |
AC50 (functional) | = 15.84893192 uM | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c19 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference |
Potency (functional) | 0.0158 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Potency (functional) | 0.7079 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Eta. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588636] | ChEMBL. | No reference |
Potency (functional) | 3.1623 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 6.3096 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent). (Class of assay: confirmatory) [Related pubchem assays: 2158 (Confirmation qHTS Assay for Inhibitors of Cruzain), 2249 (Probe Development Summary of Promiscuous Inhibitors (Artifacts) of Cruzain), 2161 (qHTS Assay for Inhibitors of Papain: Counterscreen for Cruzain Assay), 1478 (qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent))] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.